Edgewise Therapeutics (EWTX) said Wednesday that it priced an underwritten offering of about 9.9 million common shares at $20.13 per share for total proceeds of about $200 million.
Proceeds from the offering, which is set to close Thursday, will be used to support the potential US commercial launch of sevasemten in patients with Becker muscular dystrophy and advance sevasemten's phase 3 trial in Duchenne muscular dystrophy.
Remaining proceeds will also be used for the ongoing research and development programs, as well as for general corporate purposes, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.